Anti Cardiolipin Antibodies Puns

Like the title says, I have a Positive ANA (homogenous & speckled pattern, both 1:320 titer) and Positive Anti-Cardiolipin Antibody test (24 U / mL). All my other autoimmune tests were negative. I have joint pain (hands, feet, elbows, and knees) without swelling. I have fatigue. I tire quickly during physical activity and become out of breath easily. I have brain fog and am struggling with my memory - forgetting words while talking and forgetting people's names while I'm conversing with them. I've had bruises appear on the big toe on my left foot.

The first rheumatologist wants to follow me but didn't have any ideas. My second rheumatologist said the ANA was probably a fluke. Google led me to lupus.

Any thoughts?

Hi all. I had two miscarriages last year; six weeks in June and nine weeks in November. (I also am pretty sure I’m having a chemical as we speak, so I’m pretty much at a loss.) ANYWAY, my OB sent me to a fertility doc for a work up and she called me yesterday with my RPL panel results and my aCL antibodies were “intermediate.” She said this can be a blood clotting issue & she thinks it may be the cause of my losses & wants to put me on Lovenox (for this pregnancy if it ends up working out, but if not, the next one).

Curious if anyone has gotten similar results &/or any experience taking Lovenox during your pregnancy. Appreciate it!

Hi all - I’ve been diagnosed with either lupus or MCTD (depending who you ask) for about 3 years now, symptoms for much longer.

Recently in the blood work my rheumatologist requests, my igm acl antibodies are climbing up (“weak positive” so far - higher than normal reference range but not off the charts). The igg and iga are normal range.

I have read that this can be indicative of different problems in lupus patients. Does anyone have experience with this? I’m not sure how concerned I should be. Thanks.

After going through a recurrent miscarriage panel of blood tests, it looks like I'm positive for anti cardiolipin antibodies. We're back at TTC, and I've been told to start on an aspirin regimen when I ovulate and once I get a BFP they'll take another look to see if they want to put me on heparin.

I have my annual exam coming up next week. Does anyone have any experience with this? I'm going to ask what this means for my non-pregnancy/conception health, as it is an auto-immune issue.

EDIT: Realized I misspelled "heparin." It looks like this is an issue of interest for a few ladies.

Hi all- hopefully this is worth the standalone. TW: mention of losses.

Has anyone dealt with positive cardiolipin IgM while TTC or in pregnancy? I have one LC and have had 3 first trimester miscarriages while trying for a second child. We did a RPL panel which revealed that I have a balanced translocation as well as mildly elevated cardiolipin IgM. Everything else in my RPL panel came back normal (beta-2 glycoprotein, lupus anticoagulant, cardiolipin IgG) but my cardiolipin IgM has stayed low-positive (22-33) even after a 6 week repeat.

We are doing IVF with PGT-SR due to my translocation and will be doing a FET sometime in the next month or so. My RE thinks the translocation is the most likely cause of my recurrent losses (and obviously I had a successful pregnancy despite this) but wants me to see a hematologist to consider aspirin or heparin prior to transfer and during any potential pregnancy. The literature I've found is borderline as to whether that's necessary in low-positive cases (and I will certainly talk to the hematologist about pros/cons) but wondering if anyone has any experience of their own to share in the meantime. Thanks!

Hi, may I ask the group who has experience having positive protein s deficiency, anti-cardiolipin and drvtt results.

My doctor just said I'm high risk for a stroke or heart problems and my kidneys are showing signs of damage because of high protein in my urine tests. Also a possibility of lupus but it is not conclusive since I tested negative on so many anti tests (ana panel tests) . After that he prescribed me a bunch of medicines to prevent these problems.

A lot of anti-vaxxers have been arguing that the vaccines are bad because they're not "natural" like their "god-given" immune system. They also argue that the vaccines are bad because they were developed and tested with (but don't contain) fetal tissue cells.

But they sure are desperately begging for the antibody treatments when they get a bad case of COVID-19, or in some cases, just a tickle in their throat. And guess what, those are lab-made antibodies, and they were developed and tested using fetal cells. All of the things that they claim are bad.

And yet the vaccine gives your body instructions on how to make its own antibodies, which is much more natural than pumping yourself full of lab-made antibodies.

So which is more natural? The vaccine, or the antibody treatments? It seems like the vaccine is.

I know that I'm probably preaching to the choir but, for those who find themselves in conversations with anti-vaxxers, arguing the science usually isn't going to work. You have to dumb it down as much as possible and point out their own contradictions in a blindingly obvious way, to even get a microscopic hint of self-awareness out of them.

Anyone else ever had this issue? I've been having massive gut problems for over a year, despite being strict gluten free for 10 years since I was formally diagnosed by biopsy and bloodwork.

I make everything from scratch and don't ever mess with may contains. My doc sent me for a GI Map test and the immune response section returned iGa over 6000 (the max they can measure) and anti gliadin antibodies also pinned at 500. Doc is confused, I'm confused. It doesn't make any sense to me at all.

10 years of eating home cooked food and being ultra strict, always spending extra for certified components.

Just wondering if anyone else has had this.

I know diagnostic reliability of Gi map is not reliable for diagnosing celiac, that's not why I did the test. Just floored that after a decade of gluten free its still showing up somehow in my diet.

My wife is very strict about not bringing gluten in the home at all. She eats the same as me despite not needing to. So cross contamination risk is low. But somehow some must still be getting through right??

NY state health department notice on elgibility (bottom half of page 2)

Lack of DPA usage on COVID treatments.

This is a bit awkward as I don't want to throw shade on Covid vaccinations or vaccination policy (I'm not a medical professional - I'm simply a concerned LC sufferer), however - anyone reading the information at the end of last year about a possible cascading auto-immune response issue with anti idiotype antibodies, will be left wondering whether any spike protein exposure is a potential risk (Covid or otherwise).

Right now, I'm in a position where I've had 2 x Pfizer jabs, and now the NHS are repeatedly asking me for a booster. It's likely that 'vaccinated status' will soon change to mandate 3 jabs for qualification here in the UK.

If I'm to have a booster, in light of the anti idiotype' conundrum, I'd be keen to avoid anything that instructs my body to churn out spike proteins.

What are our vaccine choices here? Does something like the AstraZeneca jab operate differently enough to mitigate the risks posed by the high presence of spike proteins or can we expect the same outcomes regardless.

Just to be clear once more - I'm not saying this is definitive, but in the absence of consensus, I think we have to make up our own minds about how we navigate the Long Covid waters. I'm not interested in vaccine good or bad, but I am keen to know if any are significantly different in their operation - enough to mitigate the scenarios described here.

UC Davies summary of research: https://health.ucdavis.edu/newsroom/news/headlines/antibodies-mimicking-the-virus-may-explain-long-haul-covid-19-rare-vaccine-side-effects/2021/11

Video summary of potential issue: https://www.youtube.com/watch?v=kE9UUX7NV5Q

Has anyone here gotten their Anti-Ace 2 antibody scores tested, via, for example a CellTrend panel? If so, what did the results show? Thanks!

Hey guys! I recently got some diagnostic findings that I can't really make a deal of. Two months ago I had some I had some lab done to check for connective tissue disorders because my lungs used to collapse every few months. Lupus really wasn't the suspected diagnosis (because there's no association with pneumothorax at all) but as an incidental finding the anti dsdna antibodies were highly elevated. At first we thought of a lab mistake but two months later we got the same finding. ANA's and complement factors were normal but anti dsdna's were highly above the norm. My cardiologist then consulted a specialist for rheumatism. He told us that these antibodies can be a very specific predictor for lupus and my parameters for lupus and kidneys should be monitored at very close intervals to start treatment as soon as possible.

I'm pretty confused of all of this. I've never had any lupus symptoms and don't know what to expect now. I work in health care myself and looked it up in the medical literature but couldn't find the answers I was looking for. I love my challenging job and I've worked really hard to get here. This situation gives me a lot of unpleasant thoughts what might happen if I lose the ability to put in my efforts due to personal health reasons. I'm sorry if this sounds egoistic. Maybe somebody else here was in a similar situation one day and can give me some thoughts about it. I would be very thankful. Wishing you all nice christmas holidays!

There was recently a study relating anti-glycine receptor antibodies and VSS. Has anyone tested for these? Has any doctor suggested this testing to you?

Edit: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8591117/

Yes another piece of INOVIO's priceless pipeline is in the spotlight!!!!!!.....Can someone post the link since I am a tech klutz LOL

Would this also reduce the need for boosters?

From https://www.nature.com/articles/nrd4278/.

Given that we are entering into a period of potentially "endless" boosters, this is particularly relevant.

SHANGHAI and SEOUL, South Korea, Dec. 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and ImmuneOncia Therapeutics, Inc., a clinical-stage, immuno-oncology company in South Korea, today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in the development and manufacturing of IOH-001, ImmuneOncia's therapeutic bispecific antibody targeting PD-L1 and CD47.

Within the partnership, ImmuneOncia will have access to WuXi Biologics' integrated services in cell line development, cell culture development, biologics manufacturing and bioassay development. WuXi Biologics will support ImmuneOncia on the whole CMC studies of IOH-001 for Investigational New Drug (IND) application.

Heung Tae Kim, CEO of ImmuneOncia, commented, "We are excited to collaborate with WuXi Biologics. WuXi Biologics' comprehensive capabilities on bispecifics development and manufacturing will enable us to focus on realizing the therapeutic potential of IOH-001. More importantly, access to WuXi Biologics' world-leading technologies will help ensuring its efficacious and sustainable development. We look forward to expanding collaboration in the future to bring more innovative biologics for patients in South Korea. "

Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are glad to partner with ImmuneOncia to proceed its first bispecific antibody into clinical development through our integrated services and know-how. At WuXi Biologics, we have demonstrated our extensive capabilities for CMC development, analytical method, and quality control by enabling over 60 bispecific projects. We are committed to providing innovative technical solutions, reliable and sustainable manufacturing supply chain for our global partners to benefit patients worldwide."

About ImmuneOncia Therapeutics, Inc.

ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan Corporation in South Korea and Sorrento Therapeutics, Inc. in U.S. ImmuneOncia leverages both companies' expertise in drug development and antibody engineering. The company's mission is to bring safe, effective, and novel immunotherapies to oncology patients world-wide, and its diverse immune checkpoint inhibitor portfolio includes an anti-PDL1 antibody IMC-001 in Phase II, and an anti-CD47 antibody IMC-002 in Phase I. For IMC-002, ImmuneOncia signed a

Question in title.

SHANGHAI and SEOUL, South Korea, Dec. 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and ImmuneOncia Therapeutics, Inc., a clinical-stage, immuno-oncology company in South Korea, today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in the development and manufacturing of IOH-001, ImmuneOncia's therapeutic bispecific antibody targeting PD-L1 and CD47.

Within the partnership, ImmuneOncia will have access to WuXi Biologics' integrated services in cell line development, cell culture development, biologics manufacturing and bioassay development. WuXi Biologics will support ImmuneOncia on the whole CMC studies of IOH-001 for Investigational New Drug (IND) application.

Heung Tae Kim, CEO of ImmuneOncia, commented, "We are excited to collaborate with WuXi Biologics. WuXi Biologics' comprehensive capabilities on bispecifics development and manufacturing will enable us to focus on realizing the therapeutic potential of IOH-001. More importantly, access to WuXi Biologics' world-leading technologies will help ensuring its efficacious and sustainable development. We look forward to expanding collaboration in the future to bring more innovative biologics for patients in South Korea. "

Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are glad to partner with ImmuneOncia to proceed its first bispecific antibody into clinical development through our integrated services and know-how. At WuXi Biologics, we have demonstrated our extensive capabilities for CMC development, analytical method, and quality control by enabling over 60 bispecific projects. We are committed to providing innovative technical solutions, reliable and sustainable manufacturing supply chain for our global partners to benefit patients worldwide."

About ImmuneOncia Therapeutics, Inc.

ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan Corporation in South Korea and Sorrento Therapeutics, Inc. in U.S. ImmuneOncia leverages both companies' expertise in drug development and antibody engineering. The company's mission is to bring safe, effective, and novel immunotherapies to oncology patients world-wide, and its diverse immune checkpoint inhibitor portfolio includes an anti-PDL1 antibody IMC-001 in Phase II, and an anti-CD47 antibody IMC-002 in Phase